1. Home
  2. SPE vs ACHV Comparison

SPE vs ACHV Comparison

Compare SPE & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Special Opportunities Fund Inc

SPE

Special Opportunities Fund Inc

HOLD

Current Price

$13.87

Market Cap

154.0M

Sector

Finance

ML Signal

HOLD

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$4.72

Market Cap

172.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPE
ACHV
Founded
1993
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.0M
172.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SPE
ACHV
Price
$13.87
$4.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$14.67
AVG Volume (30 Days)
31.3K
1.2M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
8.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.43
$2.00
52 Week High
$15.99
$6.15

Technical Indicators

Market Signals
Indicator
SPE
ACHV
Relative Strength Index (RSI) 39.01 49.68
Support Level $13.95 $4.65
Resistance Level $14.12 $4.98
Average True Range (ATR) 0.18 0.42
MACD -0.07 -0.10
Stochastic Oscillator 19.30 18.80

Price Performance

Historical Comparison
SPE
ACHV

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: